222 related articles for article (PubMed ID: 27557507)
1. Sensitizing thermochemotherapy with a PARP1-inhibitor.
Oei AL; Vriend LE; van Leeuwen CM; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJ; Crezee J; Kanaar R; Kok HP; Krawczyk PM; Franken NA
Oncotarget; 2017 Mar; 8(10):16303-16312. PubMed ID: 27557507
[TBL] [Abstract][Full Text] [Related]
2. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
Oei AL; van Leeuwen CM; Ahire VR; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJA; Crezee J; Kok HP; Krawczyk PM; Kanaar R; Franken NAP
Oncotarget; 2017 Apr; 8(17):28116-28124. PubMed ID: 28427225
[TBL] [Abstract][Full Text] [Related]
3. Marked contribution of alternative end-joining to chromosome-translocation-formation by stochastically induced DNA double-strand-breaks in G2-phase human cells.
Soni A; Siemann M; Pantelias GE; Iliakis G
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():2-8. PubMed ID: 26520366
[TBL] [Abstract][Full Text] [Related]
4. DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.
Kopa P; Macieja A; Pastwa E; Majsterek I; Poplawski T
Mol Biol Rep; 2021 Jan; 48(1):709-720. PubMed ID: 33389482
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
[TBL] [Abstract][Full Text] [Related]
6. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
Jiang Y; Yam JC; Chu WK
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADPR)polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines.
Gambi N; Tramontano F; Quesada P
Biochem Pharmacol; 2008 Jun; 75(12):2356-63. PubMed ID: 18468580
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
[TBL] [Abstract][Full Text] [Related]
9. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
10. Parp1-XRCC1 and the repair of DNA double strand breaks in mouse round spermatids.
Ahmed EA; de Boer P; Philippens ME; Kal HB; de Rooij DG
Mutat Res; 2010 Jan; 683(1-2):84-90. PubMed ID: 19887075
[TBL] [Abstract][Full Text] [Related]
11. The absence of Ku but not defects in classical non-homologous end-joining is required to trigger PARP1-dependent end-joining.
Mansour WY; Borgmann K; Petersen C; Dikomey E; Dahm-Daphi J
DNA Repair (Amst); 2013 Dec; 12(12):1134-42. PubMed ID: 24210699
[TBL] [Abstract][Full Text] [Related]
12. Telomere-Internal Double-Strand Breaks Are Repaired by Homologous Recombination and PARP1/Lig3-Dependent End-Joining.
Doksani Y; de Lange T
Cell Rep; 2016 Nov; 17(6):1646-1656. PubMed ID: 27806302
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of homologous recombination by hyperthermia shunts early double strand break repair to non-homologous end-joining.
Bergs JW; Krawczyk PM; Borovski T; ten Cate R; Rodermond HM; Stap J; Medema JP; Haveman J; Essers J; van Bree C; Stalpers LJ; Kanaar R; Aten JA; Franken NA
DNA Repair (Amst); 2013 Jan; 12(1):38-45. PubMed ID: 23237939
[TBL] [Abstract][Full Text] [Related]
14. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
Bhattacharjee S; Nandi S
IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
[TBL] [Abstract][Full Text] [Related]
15. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
[TBL] [Abstract][Full Text] [Related]
16. MCL-1 dependency of cisplatin-resistant cancer cells.
Michels J; Obrist F; Vitale I; Lissa D; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Castedo M; Kroemer G
Biochem Pharmacol; 2014 Nov; 92(1):55-61. PubMed ID: 25107702
[TBL] [Abstract][Full Text] [Related]
17. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
Reilly NM; Yard BD; Pittman DL
Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
[TBL] [Abstract][Full Text] [Related]
18. PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation.
IJff M; van Bochove GGW; Whitton D; Winiarczyk R; Honhoff C; Rodermond H; Crezee J; Stalpers LJA; Franken NAP; Oei AL
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33926008
[TBL] [Abstract][Full Text] [Related]
19. Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
Du W; Amarachintha S; Wilson AF; Pang Q
Sci Rep; 2016 Feb; 6():22167. PubMed ID: 26916217
[TBL] [Abstract][Full Text] [Related]
20. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.
Metzger MJ; Stoddard BL; Monnat RJ
DNA Repair (Amst); 2013 Jul; 12(7):529-34. PubMed ID: 23684799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]